CD58 Alteration Testing for CAR-T Therapy Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapies face challenges with resistance and relapse due to CD19 loss, particularly in B-cell acute lymphoblastic leukemia (B-ALL) and large B-cell lymphoma (LBCL), necessitating improved strategies for generating therapeutic cells that can persist and maintain efficacy despite molecular alterations in CD58 activity.
Innovation Solution
Methods and systems for diagnosing and treating health conditions associated with CD58 alterations, including kits for assessing CD58 expression and molecular alterations, and systems for determining responsiveness and optimizing CAR-T cell therapy, which involve detecting CD58 expression levels or alterations using nucleic-acid and protein-based assays, and administering CAR-T cell therapy with CD2 signaling domains to overcome CD58 loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cell therapy is administered to treat B-cell malignancies, then therapeutic efficacy is improved, but resistance and relapse occur due to CD19 loss
Solution Approach 1:
The patent employs dual-targeting CAR-T cells that can recognize and bind to both CD19 and CD58 antigens simultaneously. This multi-functionality ensures that the CAR-T cells remain effective even when one target antigen is lost or downregulated, preventing resistance and relapse while maintaining therapeutic efficacy
2Productivity
If CD19-targeted CAR-T cells are used, then complete remission is achieved in many patients, but CD19 loss becomes the most common cause of relapse
Solution Approach 1:
The patent changes the targeting parameters by incorporating multiple antigen targets (CD19 and CD58) instead of relying solely on CD19. This parameter change ensures that even when CD19 expression is lost or downregulated, the CAR-T cells can still recognize and eliminate target cells through CD58, thereby maintaining long-term remission stability
3Ease of manufacture
If standard CAR-T therapy is administered, then treatment is provided, but diagnostic methods to identify resistance mechanisms are insufficient
Solution Approach 1:
The patent implements preliminary diagnostic testing to detect CD58 expression levels and molecular alterations before administering CAR-T cell therapy. This preliminary action allows clinicians to identify patients who may benefit from dual-targeting approaches and to monitor for resistance mechanisms early, improving both treatment planning and outcome prediction
Data Source
AI summary
The present disclosure generally relates to, inter alia, methods, kits, and systems for the diagnosis and/or treating various health conditions, such as proliferative disorders (e.g., cancers), associated with a decreased level or a loss of CD58 expression or molecular alterations in CD58 activity.